Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Article in English | WPRIM | ID: wpr-878294

ABSTRACT

Objective@#This research was performed to evaluate the effect of tebuconazole (TBZ) on reproductive organs of male rats and to assess the protective role of combined essential trace elements in alleviating the detrimental effect of TBZ on male reproductive function.@*Methods@#For this purpose, 48 rats were exposed to 100 mg/kg TBZ, TBZ supplemented with zinc (Zn), selenium (Se), copper (Cu), and iron (Fe), TBZ + (Se + Zn); TBZ + Cu; or TBZ + Fe. The experiment was conducted for 30 consecutive days.@*Results@#TBZ caused a significant perturbation in mineral levels and reduction in reproductive organs weights, plasma testosterone level, and testicular antioxidant enzyme activities. The TBZ-treated group also showed a significant increase in sperm abnormalities (count, motility, and viability percent), plasma follicle-stimulating hormone and luteinizing hormone concentrations, lipid peroxidation, protein oxidation, and severe DNA degradation in comparison with the controls. Histopathologically, TBZ caused testis impairments. Conversely, treatment with trace elements, in combination or alone, improved the reproductive organ weights, sperm characteristics, TBZ-induced toxicity, and histopathological modifications in testis.@*Conclusion@#TBZ exerts significant harmful effects on male reproductive system. The concurrent administration of trace elements reduces testis dysfunction, fertility, and toxicity induced by TBZ.


Subject(s)
Animal Feed/analysis , Animals , Antioxidants/metabolism , Diet , Dietary Supplements/analysis , Fungicides, Industrial/adverse effects , Male , Minerals/metabolism , Mutagenicity Tests , Rats , Rats, Wistar , Spermatozoa/physiology , Testis/physiology , Trace Elements/metabolism , Triazoles/adverse effects
2.
Arch. argent. pediatr ; 116(3): 451-454, jun. 2018. tab
Article in Spanish | LILACS, BINACIS | ID: biblio-950025

ABSTRACT

La información sobre el uso de posaconazol en niños es escasa. Se realizó este estudio descriptivo retrospectivo entre agosto de 2010 y marzo de 2017 para evaluar las características clínicas, microbiológicas y la evolución de los pacientes tratados con posaconazol. Se incluyeron 16 niños. Mediana de edad: 161 meses (rango intercuartílico -RIC- 69-173 m). Todos tenían enfermedad subyacente y presentaban infección fúngica invasiva probada. Los aislamientos más frecuentes fueron Mucor spp. y Aspergillus spp. La dosis media de posaconazol fue 600 mg/día (400-800 mg/día) y la mediana de duración del tratamiento, 223 días (RIC 48-632). Diez pacientes presentaron efectos adversos, pero solo uno requirió suspensión del antifúngico debido a alteraciones hidroelectrolíticas.


There is limited information on the use of posaconazole in children. This retrospective and descriptive study was conducted to evaluate the clinical, microbiological characteristics and evolution of patients treated with posaconazole between August 2010 and March 2017. We included 16 children. Median age: 161 months (interquartile range -IQR-69-173m). All had underlying disease and a proven invasive fungal infection. The most frequent isolated were Mucor spp. and Aspergillus spp. The mean posaconazole dose was 600 mg /day (400-800 mg/day) and the median duration of treatment was 223 days (IQR 48-632). Ten patients had adverse effects, but only one required suspension of the antifungal treatment due to hydroelectrolytic disorders.


Subject(s)
Humans , Child, Preschool , Child , Adolescent , Triazoles/therapeutic use , Invasive Fungal Infections/drug therapy , Antifungal Agents/therapeutic use , Time Factors , Triazoles/administration & dosage , Triazoles/adverse effects , Retrospective Studies , Dose-Response Relationship, Drug , Tertiary Care Centers , Invasive Fungal Infections/microbiology , Hospitals, Pediatric , Antifungal Agents/administration & dosage , Antifungal Agents/adverse effects
3.
An. bras. dermatol ; 92(5,supl.1): 59-61, 2017. tab, graf
Article in English | LILACS | ID: biblio-887080

ABSTRACT

Abstract Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in serum creatinine and transaminases, skin rashes, such as maculopapular and urticarial eruptions, have also been reported. This study reports a case of myelodysplastic syndrome with urticarial vasculitis due to deferasirox therapy. Drug eruption was been confirmed by means of a challenge test, together with histopathological and clinical findings. To the best of our knowledge, we report the first case of deferasirox-induced urticarial vasculitis. Physicians should be aware of the possibility of urticarial vasculitis on deferasirox therapy and the fact that the discontinuation of the drug generally results in improvement.


Subject(s)
Humans , Female , Aged , Triazoles/adverse effects , Urticaria/chemically induced , Vasculitis/chemically induced , Benzoates/adverse effects , Myelodysplastic Syndromes/drug therapy , Iron Chelating Agents/adverse effects , Drug Eruptions/etiology , Urticaria/pathology , Vasculitis/pathology , Biopsy , Drug Eruptions/pathology
4.
Evid. actual. práct. ambul ; 19(3): 93-93, 2016.
Article in Spanish | LILACS | ID: biblio-1151764

ABSTRACT

El posaconazol es un antifúngico de amplio espectro de la familia de los triazólicos que se utiliza en el tratamiento y profilaxis de infecciones micóticas invasivas en pacientes de 13 años de edad o mayores, en las cuales otros tratamientos no han sido eficaces o tolerados. En junio de 2016 la Agencia Europea de Medicamentos y la Agencia Española de Medicamentos y Productos Sanitarios emitieron un alerta donde advierten que debido a diferencias en la frecuencia de dosificación, interacción con los alimentos y en los niveles plasmáticos alcanzados por el medicamento, los comprimidos y la suspensión de posaconazol no son intercambiables. (AU)


Posaconazole is a broad-spectrum triazole family antifungal used in the treatment and prophylaxis of invasive fungal infections in patients 13 years of age or older, in which other treatments have not been effective or tolerated. In June 2016 the European Medicines Agency and the Spanish Agency for Medicines and Health Products issued a warning alerting that because of differences in the frequency of dosing, interactions with food and plasma levels achieved by the drug, tablets and posaconazole suspension are not interchangeable. (AU)


Subject(s)
Humans , Male , Female , Adolescent , Adult , Young Adult , Triazoles/pharmacokinetics , Antifungal Agents/pharmacokinetics , Triazoles/administration & dosage , Triazoles/adverse effects , Administration, Oral , Medication Errors , Mycoses/drug therapy , Antifungal Agents/administration & dosage , Antifungal Agents/adverse effects
6.
Yonsei Medical Journal ; : 1234-1240, 2013.
Article in English | WPRIM | ID: wpr-74278

ABSTRACT

PURPOSE: Posaconazole is a second-generation triazole with a broad spectrum. However, there is a lack of data to support a significant role for posaconazole in the treatment of invasive fungal infection (IFI), especially in Korea. Until recently, posaconazole was available only through the Korean Orphan Drug Center. This study was designed to review the use of posaconazole at a single-center in Korea. MATERIALS AND METHODS: Data from patients who received posaconazole treatment at Catholic Blood and Marrow Transplantation Center were retrospectively reviewed between January 2007 and September 2012. RESULTS: A total of 11 cases (3 males and 8 females, median age 52 years) received posaconazole. Five patients were given the drug for mucormycosis, two for invasive aspergillosis, and four for unspecified IFI for which galactomannan (GM) assays were negative. The treatment duration ranged from 4-250 days. Three patients received posaconazole for management refractory IFI, two for intolerance of previous antifungal therapy, and six for long-term maintenance treatment. The overall successful response rate to posaconazole was 55% (six of eleven patients). Five of eleven patients died during the study period. However, only one death was attributed to the progression of IFI. None of the patients discontinued posaconazole therapy due to adverse events. CONCLUSION: Posaconazole is an attractive oral antifungal agent for salvage treatment of IFI, particularly upon diagnosis of mucormycosis or in cases in which mucormycosis cannot be ruled out due to a negative GM.


Subject(s)
Adult , Aged , Antifungal Agents/adverse effects , Female , Humans , Immunocompromised Host , Male , Middle Aged , Mucormycosis/drug therapy , Mycoses/drug therapy , Republic of Korea , Salvage Therapy/adverse effects , Triazoles/adverse effects
7.
West Indian med. j ; 61(9): 932-936, Dec. 2012. ilus
Article in English | LILACS | ID: lil-694370

ABSTRACT

The use of new antiretroviral drugs in HIV infection is particularly important in patients with intolerance or resistance to other antiretroviral agents. Raltegravir and maraviroc represent new, important resources in salvage regimens. A reduced grade of liver fibro-steatosis after a combination of raltegravir and maraviroc (second-line) has not been studied and the mechanism by which these new drug classes induced a marked reduction of grade of liver diseases is currently unknown. In the present case report, nested in an ongoing multicentre observational study on the use of new antiretroviral inhibitors in heavy treatment-experienced HIV patients, we evaluated the correlation between a "short therapeutic regimen" raltegravir, maraviroc and fosamprenavir and liver diseases. The aim of this report is to describe the use of a three-drug regimen based on two novel-class antiretroviral agents (raltegravir and maraviroc) plus the protease inhibitor fosamprenavir, in an experienced HIV-infected patient with chronic progressive hepatitis C complicated by liver fibrosis; an overwhelming increased serum creatine kinase level occurred during treatment, and is probably related to integrase inhibitor administration. At present no information is available regarding this correlation.


El uso de nuevos medicamentos antiretrovirales para la infección por VIH es particularmente importante en los pacientes con intolerancia o resistencia a otros agentes antiretrovirales. Raltegravir (RTV) y maraviroc (MRV) representan nuevos e importantes recursos en las terapias de salvamento. Un grado reducido de fibroesteatosis hepática después de una combinación de raltegravir y maraviroc (terapia de segunda línea) no ha sido estudiado, y el mecanismo por el cual estas nuevas clases de droga indujeron una marcada reducción de grado de las enfermedades hepáticas se desconoce hasta el momento. Como parte de la realización en curso de un estudio observacional multicentro acerca del uso de nuevos inhibidores antiretrovirales en pacientes de VIH altamente experimentados en el tratamiento, en el presente reporte de caso se evalúa la correlación entre un "régimen terapéutico corto" (raltegravir, maraviroc y fosamprenavir) y las enfermedades del hígado. El objetivo de este reporte es describir el uso de un régimen de tres medicamentos - basado en dos agentes antiretrovirales de nuevo tipo (raltegravir y maraviroc) además del fosamprenavir inhibidor de la proteasa - en un paciente de VIH experimentado. El paciente también sufre de hepatitis C evolutiva, progresiva, crónica, complicada por fibrosis hepática. Durante el tratamiento, se produjo un aumento extraordinario del nivel de creatina quinasa sérica, el cual probablemente esta relacionado con la administración del inhibidor de la integrasa. Actualmente no hay información disponible con respecto a esta correlación.


Subject(s)
Adult , Humans , Male , Carbamates/adverse effects , Cardiomyopathies/drug therapy , Creatine Kinase/blood , Cyclohexanes/adverse effects , Chemical and Drug Induced Liver Injury/diagnosis , Fatty Liver/chemically induced , HIV Fusion Inhibitors/adverse effects , HIV Infections/drug therapy , HIV Integrase Inhibitors/adverse effects , HIV Protease Inhibitors/adverse effects , Hepatitis C, Chronic/drug therapy , Liver Cirrhosis/chemically induced , Organophosphates/adverse effects , Pyrrolidinones/adverse effects , Sulfonamides/adverse effects , Triazoles/adverse effects , Carbamates/therapeutic use , Cyclohexanes/therapeutic use , Drug Substitution , Drug Therapy, Combination , Fatty Liver/diagnosis , HIV Fusion Inhibitors/therapeutic use , HIV Integrase Inhibitors/therapeutic use , HIV Protease Inhibitors/therapeutic use , Liver Cirrhosis/diagnosis , Organophosphates/therapeutic use , Pyrrolidinones/therapeutic use , Sulfonamides/therapeutic use , Triazoles/therapeutic use
8.
Egyptian Journal of Hospital Medicine [The]. 2012; 49: 933-945
in English | IMEMR | ID: emr-170335

ABSTRACT

Sitagliptin is highly selective dipeptidyl peptidase-4 [DPP-4] inhibitor that is considered as one of the new oral therapies for management of type II diabetes. Because of the sitagliptin unknown effects on the endocrine part of the pancreas, especially on the cellular levels, this study was done to evaluate its effect on the endocrine part of the pancreas in experimentally-induced type II diabetic in adult albino rats. The present study was carried out on 30 adult male albino rats which were divided into; Group I [untreated control group], Group II [diabetic group], where type II diabetes had been induced via alloxan intake] and group III [treated group], where 0.14 mg/100 mg B.W. sitagliptin was given orally per day for 3 weeks after induction of type-2 diabetes. The specimens were prepared for light microscopic examination. In parallel, the related biomedical parameters such as serum glucose and serum insulin levels had been estimated, statistically analyzed and compared between the three groups. Sections of pancreas taken from diabetic rats showed morphological changes in islets of Langerhans cells in the form of pyknotic nuclei, cytoplasmic vacuolation, poor differentiation and abnormal shape and size of the cells. These morphological changes had been partially recovered in diabetic rats treated with sitagliptin. Also, the hyperglycemia and hypoinsulinemia that was detected in the control diabetic group had been nearly returned to normal after sitagliptin treatment. Sitagliptin drug has improved islet functions on both morphological and biomedical parameters in type II diabetic rats and can be taken into consideration as one of the new oral anti- diabetic drugs on the human level that need to be more investigated


Subject(s)
Animals, Laboratory , Triazoles/adverse effects , Pancreas/pathology , Histology , Diabetes Mellitus, Experimental/complications , Rats
9.
Yonsei Medical Journal ; : 863-865, 2011.
Article in English | WPRIM | ID: wpr-182764

ABSTRACT

This is a case report on a 35-year-old man with acute myelogenous leukemia who presented fever and intermittent mucoid loose stool to the emergency center. He had been taking voriconazole for invasive pulmonary aspergillosis. The flexible sigmoidoscopy was consistent with the diagnosis of pseudomembranous colitis.


Subject(s)
Adult , Antifungal Agents/adverse effects , Enterocolitis, Pseudomembranous/chemically induced , Humans , Invasive Pulmonary Aspergillosis/complications , Leukemia, Myeloid, Acute/complications , Male , Opportunistic Infections/complications , Pyrimidines/adverse effects , Triazoles/adverse effects
10.
JCPSP-Journal of the College of Physicians and Surgeons Pakistan. 2010; 20 (8): 551-553
in English | IMEMR | ID: emr-111024

ABSTRACT

Drug-induced liver injury is a common side-effect of many medicines. It is particularly problem when the original condition under treatment is already causing liver damage. This report describes the hepatotoxicity induced by Deferasirox in a patient with haemochromatosis with a discussion of possible pathogenetic mechanisum


Subject(s)
Humans , Female , Chemical and Drug Induced Liver Injury/etiology , Hemochromatosis/drug therapy , Triazoles/adverse effects , Iron Chelating Agents/adverse effects , Chelation Therapy , Treatment Outcome
11.
Journal of the Arab Society for Medical Research. 2009; 4 (2): 181-190
in English | IMEMR | ID: emr-97616

ABSTRACT

Bromuconazole, is a triazole fungicide used in enclosed commercial greenhouses was evaluated for its potential toxic effects in rat liver. Sprague-Dawley male rats were treated orally at daily doses of 36.5 and 18.25 mg/kg b. wt [1/10 and 1/20 LD[50], respectively] Bromuconazole for 3 months. Measurements include potential DNA fingerprinting using random amplified polymorphic DNA [RAPD-PCR] analysis, total nucleic acids content, total protein as well as histopathological alteration in the liver were performed. The results revealed that, Bromuconazole fungicide had genotoxic and toxicopathological effects in rat liver. The genotoxic effects were indicated by appearance of some changes in polymorphism band patterns including deletion of stable bands or insertion of new bands. The effects on the liver were also manifested by different histopathological lesions including severe necrobiotic and proliferative changes with the appearance of hepatoma at high dose. In addition, the liver tissue DNA, RNA and protein contents were significantly increased with increasing the dose of Bromuconazole. Using of Bromuconazole fungicide should be reconsidered due to its possible cytotoxic. clastogenic and mutagenic effects


Subject(s)
Animals, Laboratory , Triazoles/adverse effects , Mutagenicity Tests , Liver/pathology , Histology , Environmental Exposure , Rats
12.
Indian Pediatr ; 2008 Mar; 45(3): 236-8
Article in English | IMSEAR | ID: sea-12436

ABSTRACT

Voriconazole is a newer systemic antifungal agent effective against Candida and Aspergillus. There are few reports of its safe use in newborns. We report the first case series of safe Voriconazole use in critically ill newborns with cardiac disease along with several other cardiac drugs without any significant drug interaction or side-effect.


Subject(s)
Antifungal Agents/adverse effects , Aspergillosis/drug therapy , Aspergillus/drug effects , Candida/drug effects , Candidiasis/drug therapy , Critical Illness , Humans , Infant, Newborn , Pyrimidines/adverse effects , Triazoles/adverse effects
13.
J Cancer Res Ther ; 2007 Apr-Jun; 3(2): 71-4
Article in English | IMSEAR | ID: sea-111516

ABSTRACT

AIM: To analyze overall and progression-free survival after letrozole in postmenopausal women with advanced breast cancer who failed after tamoxifen therapy. MATERIALS AND METHODS: This is a retrospective analysis of 95 patients with breast cancer who were postmenopausal and had failed after tamoxifen therapy. Dose of letrozole was 2.5 mg daily until disease progressed. Patients had estrogen receptor- and/or progesterone receptor-positive tumors or both receptors were unknown. One complete course of (6 cycles) chemotherapy for metastatic disease was allowed. The primary end point was time to progression (TTP). Secondary end points included overall objective response rate (ORR), its duration, time to treatment failure (TTF), overall survival and tolerability. RESULTS: Median TTP was 10 months. ORR was 21% with complete response rate of 9%. Nine patients died of disease during treatment. Median overall survival was 36 months. Median time to response was three months and median duration of response was 13 months. Time to chemotherapy was 13.5 months and TTF was 9.3 months. Treatment failure was seen in 76% of patients. Disease progression was the main cause for treatment failure. Treatment was well-tolerated by all patients. CONCLUSION: This retrospective analysis shows that letrozole is quite effective as second line therapy in postmenopausal patients with advanced breast cancer who had failed after tamoxifen therapy.


Subject(s)
Adult , Aged , Antineoplastic Agents/adverse effects , Aromatase Inhibitors/adverse effects , Breast Neoplasms/drug therapy , Female , Humans , Middle Aged , Nitriles/adverse effects , Postmenopause , Retrospective Studies , Tamoxifen/therapeutic use , Treatment Outcome , Triazoles/adverse effects
14.
J. bras. pneumol ; 32(5): 449-460, set.-out. 2006. ilus
Article in Portuguese | LILACS | ID: lil-452403

ABSTRACT

Aborda-se sumariamente o espectro de ação, aspectos farmacológicos e toxicológicos e eficácia clínica de anfotericina B lipossomal, anfotericina B em dispersão coloidal, complexo lipídico de anfotericina B, voriconazol e caspofungina. Discute-se o uso desses antifúngicos mais recentes considerando a segurança, a eficiência e o custo da terapia. Sugestões para o uso clínico dessas drogas em infecções pulmonares e sistêmicas são apresentadas, destacando-se a menor toxicidade das formulações lipídicas da anfotericina B em relação à medicação convencional, a possibilidade de terapia primária da aspergilose invasiva, scedosporiose e fusariose com voriconazol e a caspofungina como opção terapêutica na candidíase disseminada e na aspergilose invasiva.


We summarize here data regarding the spectrum of action, the pharmacological aspects, the toxicological aspects and the clinical efficacy of liposomal amphotericin B, amphotericin B in colloidal dispersion, amphotericin B lipid complex, voriconazole and caspofungin. We discuss the use of these more recently introduced antifungal agents in terms of their safety, efficiency and cost. We also offer suggestions for the clinical use of these drugs in pulmonary and systemic infections, with an emphasis on the lower toxicity of the lipid formulations of amphotericin B in comparison with conventional medications. In addition, we explore the possibility of using voriconazole as the primary treatment for invasive infections such as aspergillosis, as well as those caused by Scedosporium spp. and Fusarium spp., together with that of using caspofungin to treat disseminated candidiasis and invasive aspergillosis.


Subject(s)
Humans , Amphotericin B/therapeutic use , Antifungal Agents/therapeutic use , Lung Diseases, Fungal/drug therapy , Peptides, Cyclic/therapeutic use , Pyrimidines/therapeutic use , Triazoles/therapeutic use , Amphotericin B/adverse effects , Antifungal Agents/adverse effects , Echinocandins , Peptides, Cyclic/adverse effects , Pyrimidines/adverse effects , Triazoles/adverse effects
15.
Rev. Inst. Med. Trop. Säo Paulo ; 47(6): 339-346, Nov.-Dec. 2005. ilus, tab
Article in English | LILACS | ID: lil-420088

ABSTRACT

Eumicetoma e cromoblastomicose são infecções fúngicas crônicas do tecido subcutâneo que evoluem com aspecto desfigurado, raramente involuindo espontaneamente. A maioria dos pacientes não apresenta melhora sustentada por longo tempo com os tratamentos disponíveis, sendo de grande importância as novas opções terapêuticas. A eficácia do posaconazol, um novo agente antifúngico de amplo espectro do grupo dos triazóis, foi estudada em 12 pacientes com eumicetoma ou cromoblastomicose refratária às terapêuticas antifúngicas disponíveis. Os pacientes receberam por no máximo 34 meses, doses divididas de 800 mg/dia de posaconazol. Resposta clínica parcial ou completa foi considerada como sucesso; doença estável ou falha terapêutica foi considerada como insucesso. Todos os 12 pacientes tinham infecções comprovadas ou prováveis, refratárias à terapêutica padrão preconizada. Sucesso clínico foi registrado em cinco de seis pacientes com eumicetoma e cinco de seis pacientes com cromoblastomicose. Em dois pacientes observou-se doença estável. Como parte do protocolo de extensão do tratamento, dois pacientes com eumicetoma que inicialmente tinham tido sucesso terapêutico e que após um intervalo maior de 10 meses apresentaram recidiva da micose, foram retratados com sucesso com posaconazol. Posaconazol foi bem tolerado durante o longo período de administração (até 1015 dias). A terapêutica com posaconazol foi seguida de sucesso na maioria dos pacientes com eumicetoma ou cromoblastomicose refratária à terapêutica padrão, sugerindo que tal droga possa ser uma importante opção no tratamento de tais doenças.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Antifungal Agents , Chromoblastomycosis/drug therapy , Mycetoma/drug therapy , Triazoles/therapeutic use , Antifungal Agents , Chromoblastomycosis/microbiology , International Cooperation , Mycetoma/microbiology , Treatment Outcome , Triazoles/adverse effects
16.
J Cancer Res Ther ; 2005 Apr-Jun; 1(2): 75-8
Article in English | IMSEAR | ID: sea-111368

ABSTRACT

PURPOSE: AK-2123, a nitrotriazole hypoxic cell sensitizer has reportedly improved results in head and neck cancers, uterine cervical cancers and other solid tumours when added to radical radiotherapy. A prospectively randomised trial was initiated by the International Atomic Energy Agency (IAEA) evaluating AK-2123 and radiotherapy in treatment of uterine cervical cancer stage IIIA and IIIB. MATERIALS AND METHODS: A total of 333 patients were randomised between May 1995 and December 1998. Patients were randomised to either standard radical treatment (radiation therapy alone, RT) or standard radical radiotherapy and additional administration of AK-2123 (RT+AK-2123). The total dose of 45-50.8 Gy was delivered in 20 to 28 fractions over 4 to 5 1/2 weeks. The dose to the central disease was escalated to a radiobiologically equivalent dose of 70 Gy by external beam or brachytherapy, in accordance with each centres individual practice. In the study arm, patients received 0.6 g/sqm AK-2123 by intravenous administration before external beam radiotherapy, treating with AK-2123 on alternate days (e.g. Monday-Wednesday-Friday) during the entire course of external beam therapy. RESULTS: After a median follow up of 57 months (range 30-73 months) the rate of local tumour control was significantly higher in the group who received radiotherapy and additional administration of AK-2123. Local tumour control at the last follow up was 61% after combined radiotherapy and AK-2123 and 46% after radiotherapy alone (p = 0.005). AK-2123 neither increased gastro-intestinal toxicity nor gave any haematological toxicity. A mild peripheral neuropathy (Grade 1:11% and Grade 2:3%) was seen infrequently after AK-2123 administration and was usually completely reversible. Crude survival rates were 41% after radical treatment compared to 57% after combined therapy (p = 0.007). CONCLUSION: We conclude that the addition of AK-2123 to radical radiotherapy significantly increases response rates and local tumour control in advanced squamous cell cancer of the uterine cervix without any increase in major toxicity. Further analysis and follow up are needed to evaluate if this benefit will translate into prolonged survival. We strongly suggest that our initially very promising study should lead other centres to further studies of AK-2123 in randomised clinical trials.


Subject(s)
Female , Humans , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Radiation-Sensitizing Agents/therapeutic use , Triazoles/adverse effects , Uterine Cervical Neoplasms/pathology
17.
Indian J Cancer ; 2002 Jun; 39(2): 39-44
Article in English | IMSEAR | ID: sea-49287

ABSTRACT

AK-2123, is a nitrotriazole with a potential to sensitize hypoxic tissue to radiation. Cancer of cervix in advanced stages are predominantly treated with radiation. These are the tumours which harbour a large hypoxic core. This is an Indian experience of the multicentric trial. Patients were randomized to control and AK-2123 arm. 49 patients were randomized to each group. Patients received external radiation with telecobalt to a dose of 50 Gy in five weeks. Those in the study arm received 600 mg/m2, on alternate days. The patients were further treated with intracavitory radiation a dose of 20 Gy. The total dose of 70 Gy was achieved. Patients in the study arm had a complete response of 71.43% (35 of 49) while only 21 of 49 (42.86%) responded in the control group. The overall survival at two years was 72.2% for the study group and 32.43% for control. Neuropathy, a drug related toxicity was transient except, in one patient, which has persisted. AK-2123, has shown significant radiation sensitizing potential.


Subject(s)
Adult , Aged , Female , Humans , India/epidemiology , Middle Aged , Nervous System Diseases/etiology , Radiation-Sensitizing Agents/adverse effects , Radiotherapy Dosage , Survival Rate , Triazoles/adverse effects , Uterine Cervical Neoplasms/drug therapy
18.
Rev. invest. clín ; 54(3): 192-197, mayo-jun. 2002.
Article in Spanish | LILACS | ID: lil-332928

ABSTRACT

OBJECTIVE: To determine the frequency of concurrent use of cisapride, astemizole and terfenadine with macrolides and azole antimitotics, drug combinations that have been reported in the literature as producing a pharmacological interaction associated with potentially fatal ventricular arrhythmias. MATERIAL AND METHODS: A retrospective analysis of a total of 72,444 prescriptions generated by 611 physicians during a 6 months period for ambulatory patients, was performed. The database included a register of automatic alerts produced every time a predetermined drug combination was detected. RESULTS: 145 potentially risk situations were detected, with an incidence rate to 2.1 cases per 1,000 prescriptions, which increases to 6.2 when prescriptions for terfenadine, astemizole, and cisapride were included, with 12, 9 y 5, respectively. Only 36 physicians (6) wrote prescriptions producing alerts, and about half (45) were pediatricians. The same physician prescribed both drugs in 31 of the cases. CONCLUSION: The use of drug combinations associated with a high risk of potentially fatal ventricular arrhythmias is relatively high in Mexico. An electronic online detecting system showed to be useful in preventing this kind of potential pharmacological interactions.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Astemizole , Arrhythmias, Cardiac/chemically induced , Cisapride , Online Systems , Drug Information Services/organization & administration , Terfenadine , Triazoles/adverse effects , Astemizole , Anti-Bacterial Agents/adverse effects , Antifungal Agents/adverse effects , Arrhythmias, Cardiac/epidemiology , Arrhythmias, Cardiac/prevention & control , Cisapride , Diagnosis-Related Groups , Drug Interactions , Drug Utilization , Histamine H1 Antagonists , Incidence , Mexico , Pilot Projects , Drug Prescriptions/statistics & numerical data , Managed Care Programs/organization & administration , Retrospective Studies , Risk , Pharmaceutical Services/organization & administration
20.
Medicina (B.Aires) ; 47(5): 505-8, sept.-oct. 1987. tab
Article in Spanish | LILACS | ID: lil-59177

ABSTRACT

Fueron tratados con itraconazol 13 pacientes con paracoccidioidomicosis y 13 con histoplasmosis, todos adultos de sexo masculino. Aquellos con paracoccidioidomicosis exhibieron la forma crónica tipo adulto de la enfermedad con compromiso de por lo menos dos órganos. El itraconazol fue administrado en dosis de 50mg por día tomados después del desayuno durante 6 meses. Todos las infecciones curaron a excepción de una que presentó mejoría de los parámetros clínicos, bioquímicos e inmunológicos. Doce pacientes con histoplasmosis tenían la forma diseminadada crónica, el restante presentó la forma pulmonar cavitaria crónica. La dosis de itraconazol fue de 100mg diarios en una sola toma durante 6 meses. Once infecciones fueron curadas y una presentó mejoría significativa. El paciente restante falleció debido a una intercurrencia no relacionada con la micosis. Hasta el momento de su muerte pudo demostrarse mejoría de todos los parámetros de seguimiento


Subject(s)
Adult , Middle Aged , Humans , Male , Histoplasmosis/drug therapy , Paracoccidioidomycosis/drug therapy , Triazoles/therapeutic use , Ketoconazole/therapeutic use , Triazoles/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL